sglt2 inhibitors vs glp 1 agonists or GLP-1 receptor as second-line therapy in | VHRM Cardiorenal Protection: Potential of SGLT2

Loss-of-function polymorphisms and a rare missense mutation in human CAMKK2 are associated with bipolar disorder, and genetic deletion of Camkk2 in mice causes bipolar-like behaviours similar to those in patients

3 Future studies are needed to determine whether this class of medications inhibits progression from nonexudative to neovascular or late atrophic stages of AMD

This hormone does several things simultaneously

Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, Genovese S: Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes

Batterham, R

GLP-1RAs dominate IGE-related reports Among the top 10 drugs associated with IGE events, five were GLP-1 receptor agonists: Dulaglutide: 262 cases Semaglutide: 246 cases Exenatide: 183 cases Tirzepatide: 181 cases Liraglutide: 110 cases Together, they accounted for 49.5% (982 of 1982) of the IGE reports among these top 10 drugs